Silence Therapeutics plc (SLN)
NASDAQ: SLN · IEX Real-Time Price · USD
21.23
+0.56 (2.71%)
Jul 22, 2024, 10:08 AM EDT - Market open
Silence Therapeutics Employees
Silence Therapeutics had 109 employees as of December 31, 2023. The number of employees decreased by 13 or -10.66% compared to the previous year.
Employees
109
Change (1Y)
-13
Growth (1Y)
-10.66%
Revenue / Employee
$310,598
Profits / Employee
-$410,950
Market Cap
983.68M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Avanos Medical | 3,771 |
CareDx | 643 |
BioLife Solutions | 414 |
Bicycle Therapeutics | 284 |
Tango Therapeutics | 140 |
Viridian Therapeutics | 94 |
Pharvaris | 82 |
Praxis Precision Medicines | 82 |
SLN News
- 25 days ago - Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients - Business Wire
- 4 weeks ago - Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration - Business Wire
- 4 weeks ago - Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) - Business Wire
- 7 weeks ago - Silence Therapeutics to Present at Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress - Business Wire
- 2 months ago - Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference - Business Wire
- 3 months ago - Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors - Business Wire
- 3 months ago - Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) - Business Wire